<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148509</url>
  </required_header>
  <id_info>
    <org_study_id>Z171100000117016</org_study_id>
    <nct_id>NCT03148509</nct_id>
  </id_info>
  <brief_title>A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway</brief_title>
  <official_title>Clinical Psychopharmacology Division Institute of Mental Health, Peking University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit depressed patients unresponsive to selective serotonin reuptake
      inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed
      patients, schizophrenia, Parkinson's disease with and without depression, and healthy
      controls. The subjects need to complete the brain positron emission tomography/magnetic
      resonance examination, stress assessment, genetic testing, clinical evaluation and
      neuropsychological tests. Using the data, this study aimed to identify the abnormalities of
      reward circuit of depression and its differences with other diseases, and its abnormalities
      in first-degree relatives of depression. The depressed patients who were ineffective in
      treatment with selective serotonin reuptake inhibitor antidepressants were then given
      combined medication with dopamine receptor-mediated drugs, including dopamine transporter
      inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist -
      aripiprazole, to examine the regulation of dopamine pathway and its relationship with the
      therapeutic effect. Through the above work, we will provide new evidence for integrating the
      biological evidence of dopamine reward pathway into the clinical practice of depression.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diagnosis and Treatment of Depression</condition>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>DA receptor-mediated drugs</description>
    <arm_group_label>bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>DA receptor-mediated drugs</description>
    <arm_group_label>risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>DA receptor-mediated drugs</description>
    <arm_group_label>aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients unresponsive to SSRI antidepressant treatment, first-degree relatives
             (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with
             and without depression, and healthy controls

        Exclusion Criteria:

          -  Major physical illness; other DSM-IV axis I mental illness; personality disorder,
             mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI
             examination contraindications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji-Tao Li, MD</last_name>
    <phone>010-62723742</phone>
    <email>ljt_102124@163.com</email>
  </overall_contact>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Si Tianmei</investigator_full_name>
    <investigator_title>Director of Clinical Psychopharmacology Division,Institute of Mental Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

